Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

ces with respect to the Company's clinical programs include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that preclinical data will indicate that urocortin 2 is not suitable for further clinical studies; risk that the CRF1 receptor antagonist candidate's Phase II proof of concept clinical studies will not support further clinical studies; and overall risk that the Company's clinical candidates will not proceed to later stage clinical trials. Risks associated with the Company's indiplon program include, but are not limited to, risk that indiplon approval and subsequent commercialization may be indefinitely delayed or never accomplished. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2007 and report on Form 10Q for the quarter ended June 30, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

NEUROCRINE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(in thousands, except for per share data)

Three Months Ended Nine Months Ended

September 30,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... about a billionth of a meter in size, are ... can benefit human health, as in some innovative early ... through viruses, air pollution, traffic emissions, cosmetics, sunscreen and ... in St. Louis, led by Lan Yang, PhD, the ... Systems Engineering, and their collaborators at Tsinghua University in ...
(Date:9/2/2014)... Scientists, including University of Oregon chemist Geraldine Richmond, ... of self-assembling, synthetic proteins called peptoid nanosheets that ... accomplishment -- detailed this week in a paper ... Proceedings of the National Academy of Sciences ... of the two-dimensional peptoid nanosheets that can be ...
(Date:9/2/2014)... 2, 2014 Persistence Market Research ... in Pharmaceutical, Biopharma and Life Sciences: North ... the global membrane technology market for pharmaceutical, biopharma and life sciences ... is expected to grow at a CAGR of 9.1% ... of USD 10,886.0 million in 2019. Browse ...
(Date:9/2/2014)... AVENTURA, Fla. , Sept. 2, 2014  Technology ... has announced that its wholly-owned subsidiary Renuell Int,l, Inc. ... National Aeronautics and Space Administration ("NASA") at the Johnson ... See photos: tapplic.com/houstonphotos/ ... stated, "We are very pleased to announce our latest, ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3
... that it,has received the European CE Mark (Conformite Europeene) ... CE Mark certifies,that the product has met EU health, ... Granted in the Netherlands, the,registration will allow the system ... countries around the world that recognize the CE Mark. ...
... Calif., Oct. 29 Cliniqa Corporation (San,Marcos, ... is pleased to,announce the acquisition of the ... Diego, CA), a wholly owned subsidiary of ... manufacturer of clinical,diagnostic products focusing on clinical ...
... to Focus on Sales Growth and Product ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a ... and cryopreservation media products for,cells, tissues, and ... product,manufacturing, warehousing, and customer order fulfillment to ...
Cached Biology Technology:Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening 2Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 3
(Date:9/2/2014)... most ideal source of nutrition for infants and ... the evolution and civilizations of human beings. Unlike ... number of bacterial species, including some opportunistic pathogens ... to scientists and physicians. , Indeed, the existence ... result of co-evolutionary and co-adaptive interactions between the ...
(Date:9/2/2014)... integrity? Tell the truth; everyone has a tipping point. We ... lie if the benefit is great enough. Now, scientists have ... that decision. , The result was published online this ... prefer to be honest, even if lying is beneficial," said ... at the Virginia Tech Carilion Research Institute , where ...
(Date:9/2/2014)... propensity for eating anything, including each other, camel crickets ... North Carolina State University finds that non-native camel cricket ... States. , "The good news is that camel crickets ... humans," says Dr. Mary Jane Epps, a postdoctoral researcher ... about the research. , The research stems from a ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... the triangle depicting how many servings of each food ... knows about MyPlate - the circle showing what a healthy ... United States Department of Agriculture (USDA) to help American consumers ... icon that prompts us to think about what,s on our ...
... gene therapy holds promise for the treatment of devastating genetic ... have been unclear. In a study online December 26th ... by Cell Press, researchers evaluated a patient with a genetic ... after he had undergone a gene therapy procedure as part ...
... neurodegenerative disorders, and drugs without significant side effects ... Institute of Synergon Consulting in Romania, led by ... is a transcription co-activator required for consolidation of ... same time involved in DNA replication and repair, ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2